Search results for: Health Data and Statistics
Filter search results
Raoh-Fang Pwu
15 May 2023
…She completed her training as an epidemiologist at the College of Public Health, National Taiwan University, where she developed expertise in research designs and the analysis of large/claims databases early…
EU Approval of Biosimilars
8 July 2010
…Gopalan Narayanan is a medical assessor at the MHRA (Biologicals and Biotechnology Unit) and a member of several EMEA committees and working parties. Publication now available for download: Mattison, N., Mestre-Ferrandiz, J. and…
Estimating US Savings from Biosimilars
13 July 2010
…and when any savings might appear. This is the eighth and last in our series of posts based on the OHE seminar and summarises the remarks of Alexis Ahlstrom of Avalere…
Competition in the NHS: ‘Payment by Results’
17 August 2010
…NHS in England in 2003 to stimulate provider efficiency, encourage health care purchasers to plan and manage demand better, enable patient choice, reward quality in service provision and be transparent. Money…
The UK’s Publicly Funded Vaccines Market
23 November 2010
…UK — England, Northern Ireland, Scotland and Wales — follow these recommendations. The UK has highly centralised approach to procuring vaccines. According to the 2009 NHS Constitution for England, the…
Measuring Value: OHE at ISPOR
4 January 2011
…database and additional data from public NICE documents provide the basis for analysing NICE’s decisions over the past decade. Each of decisions is characterised as a ‘yes’ or a ‘no’,…
Prospective Observational Studies: Whether, When and How to Use
18 June 2012
…Towse is co-author on the recent report by the ISPOR Good Research Practices Task Force on assessing comparative effectiveness using prospective observational studies. The demand for comparative data, and in…
Join OHE in a Seminar to Discuss IP, Innovation and the Human Genome
19 October 2012
…public Human Genome Project and the private firm Celera to investigate how Celera’s gene-level IP influenced subsequent scientific research and product development. Do intellectual property (IP) rights on existing technologies…
OHE Study on Pharmaceutical R&D Costs Released
3 December 2012
…aspects and/or siting trials in lower-cost locations. The promise of the new, gene-based sciences is tremendous. Rapidly evolving R&D technology, however, requires a wide range of expertise and data. In…